{"entity":{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","aka":[],"tldr":"Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.","summary":"Yi-Long Wu is Professor at the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and a leader of the Chinese Thoracic Oncology Group. He is among the most cited lung cancer trialists in the world, co-principal investigator of ADAURA, which tested adjuvant osimertinib in resected EGFR-mutated non-small-cell lung cancer, and a leader of IPASS and ADJUVANT-CTONG, the trials that made EGFR-targeted pills standard before and after surgery. His publications include the ADAURA report on osimertinib in resected EGFR-mutated lung cancer. His interests are EGFR-mutant disease, adjuvant targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Guangdong Lung Cancer Institute","url":"https://www.gdghospital.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":["osimertinib"],"companies":["ctong"],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":["adaura"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["Lung cancer","EGFR-mutant NSCLC","Adjuvant targeted therapy","Clinical trials"],"profiles":[{"label":"Guangdong Lung Cancer Institute","url":"https://www.gdghospital.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib"}],"papers":[{"title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer (ADAURA)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2027071"}]},"route":"/people/wu-yi-long/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/"}],"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/"}],"trial":[{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/"}],"paper":[{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/"},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/"},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/"}]}}